A Phase 4 interventional study of Desflurane and Sevoflurane-Desflurane in Obesity and Bariatric Surgery, sponsored by Clínica Dávila. Not yet recruiting at 1 site in Chile. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Clínica Dávila · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Obesity with a site in Chile — 10 open to participants now, 13 under way, 3 of them phase 3. Obesity · Chile.
Among the 47 studies in Obesity with a site in Chile, this one is the 20th largest by planned enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 7 of the 12 other live ones, and was the 46th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →10 of the 47 studies in Obesity with a site in Chile are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Chile, United States, Argentina and 13 more countries
Ages 18+
Universidad San Sebastián · Sites in Chile
Ages 18–59
Universidad Autónoma de Chile · Sites in Chile
Ages 18–60
Amgen · Sites in Chile, United States, Argentina and 32 more countries
Ages 18–99
Universidad Católica San Antonio de Murcia · Sites in Chile
Ages 18+
A study can be open while its sites in Chile have not opened yet or have stopped. Only those recruiting at a site in Chile →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 75 across the 42 interventional studies, 409 across the 5 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 47 have an industry lead sponsor. The 10 most frequent:
Clínica Dávila is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Clínica Dávila has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity with a site in Chile that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07552727Universidad San SebastiánRehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis | 2026-12-31 |
| NCT07748247Clínica DávilaSwap Anesthetic Versus Continuous Desflurane in Adults Undergoing Bariatric Surgery | 2027-04 |
| NCT06845202Alnylam PharmaceuticalsA Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies in Obesity with a site in Chile, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, parallel-group, non-inferiority clinical trial aims to evaluate whether an anesthetic swap strategy consisting of sevoflurane followed by desflurane 30 minutes before the end of surgery is non-inferior to continuous desflurane anesthesia with respect to extubation time in adults undergoing elective laparoscopic bariatric surgery. Secondary outcomes include time to achieve a Patient State Index (PSi) greater than 80, time to achieve an Aldrete score of at least 8, incidence of postoperative nausea and vomiting, post-anesthesia care unit length of stay, and desflurane-related costs.
Obesity is associated with an increased risk of postoperative respiratory complications, making rapid and safe anesthetic recovery particularly important in patients undergoing bariatric surgery. Desflurane provides rapid emergence because of its favorable pharmacokinetic profile but is associated with higher cost and greater environmental impact than sevoflurane.
This prospective, randomized, parallel-group, non-inferiority trial will compare two inhalational anesthetic strategies in adults undergoing elective laparoscopic bariatric surgery at Clínica Dávila. Participants will be randomly assigned in a 1:1 ratio to receive either continuous desflurane throughout the procedure or a swap strategy consisting of sevoflurane during most of the operation followed by desflurane beginning 30 minutes before surgical closure.
The primary outcome is extubation time, defined as the interval from discontinuation of inhaled anesthetic agents to removal of the endotracheal tube. Secondary outcomes include time to achieve a Patient State Index (PSi) greater than 80, time to achieve an Aldrete score of at least 8 in the post-anesthesia care unit, incidence of postoperative nausea and vomiting, length of stay in the post-anesthesia care unit, and desflurane-related costs. The study is designed to determine whether the swap anesthetic strategy is non-inferior to continuous desflurane while reducing desflurane consumption, with potential benefits for environmental sustainability and healthcare costs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive desflurane as the inhalational anesthetic throughout the entire elective laparoscopic bariatric surgery according to the study protocol.
Drug: Desflurane
Participants receive sevoflurane during most of the procedure and are switched to desflurane 30 minutes before the end of surgery according to the study protocol.
Drug: Sevoflurane-Desflurane
Desflurane administered as the inhalational anesthetic throughout the surgical procedure.
Sevoflurane administered during the initial phase of surgery followed by desflurane beginning 30 minutes before surgical closure.
Extubation Time
Time in seconds from discontinuation of inhaled anesthetic agents to removal of the endotracheal tube.
Time frame: Perioperative
Time to Achieve Patient State Index Greater Than 80
Time in seconds from discontinuation of inhaled anesthetic agents until the Patient State Index (PSi) reaches a value greater than 80.
Time frame: Perioperative
Postoperative Nausea and Vomiting
Presence of postoperative nausea or vomiting, recorded as a binary outcome of yes or no.
Time frame: Up to 24 hours after surgery
Time to Achieve an Aldrete Score of at Least 8
Time in minutes from arrival at the post-anesthesia care unit until the participant achieves an Aldrete score of at least 8 out of 10.
Time frame: Up to 24 hours after surgery
Time to Post-Anesthesia Care Unit Discharge Readiness
Time in minutes from arrival at the post-anesthesia care unit until the participant meets the institutional discharge criteria.
Time frame: Up to 24 hours after surgery
Desflurane-Related Cost
Estimated cost in Chilean pesos associated with desflurane use. The cost will be calculated according to the total duration of desflurane administration, using an estimated consumption of 0.75 mL per minute and a cost of 415 Chilean pesos per mL. The applied formula will be: duration of desflurane anesthesia in minutes multiplied by 311.25 Chilean pesos.
Time frame: Periprocedural (during surgery)
Plan to share: No — Individual participant data will not be made publicly available because the study involves clinical data collected at a single institution, and no data-sharing agreement or repository has been established. Only aggregate study results will be reported in scientific publications and presentations.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Apr 2027, 8 months later.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 8 months is below that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Desflurane
Clínica Dávila